C1-Inhibitor

Production of Plasma Proteins for Therapeutic Use

Volumn , Issue , 2012, Pages 241-258

  Over, Jan ^a   Kramer, Christine ^a   Koenderman, Anky ^a   Wouters, Diana ^a   Zeerleder, Sacha ^b  

^a CENTRAL LABORATORY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

C1 inhibitor in physiology; C1 inhibitor, in HAE; C1 inhibitor, native conformation; C1 inhibitor, or suicide inhibitor; MASP 2 and C1 inhibitor

Indexed keywords

EID: 84886143356     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118356807.ch17     Document Type: Chapter

References (193)

1. Ratnoff OD, Lepow IH. (1957) Some properties of an esterase derived from preparations of the first component of complement. J Exp Med, 106, 327-343.
2. Landerman NS, Webster ME, Becker EL, Ratcliffe HE. (1962) Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy, 33, 330-341.
3. Donaldson VH, Evans RR. (1963) A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C01-esterase. Am J Med, 35, 37-44.
4. Osler W. (1888) Hereditary angio-neurotic oedema. Am J Med Sci, 95, 362-367.
5. Johnson AM, Alper CA, Rosen FS, Craig JM. (1971) C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science, 173, 553-554.
6. Yeung Laiwah AC, Jones L, Hamilton AO, Whaley K. (1985) Complement-subcomponent-C1-inhibitor synthesis by human monocytes. Biochem J, 226, 199-205.
7. Katz Y, Strunk RC. (1989) Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J Immunol, 142, 2041-2045.
8. Schmaier AH, Murray SC, Heda GD, Farber A, Kuo A, McCrae K, Cines DB. (1989) Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J Biol Chem, 264, 18173-18179.
9. Haupt H, Heimburger N, Kranz T, Schwick HG. (1970) Ein Beitrag zur Isolierung und Charakterisierung des C1-Inaktivators aus Humanplasma. Eur J Biochem, 17, 254-261.
10. Sim RB, Reboul A. (1981) Preparation and properties of human C1 inhibitor. Methods Enzymol, 80, 43-54.
11. Nilsson T, Wiman B. (1982) Purification and characterization of human C1-esterase inhibitor. Biochim Biophys Acta, 705, 271-276.
12. Harrison RA. (1983) Human C1 inhibitor: improved isolation and preliminary structural characterization. Biochemistry, 22, 5001-5007.
13. Bock SC, Skriver K, Nielsen E, Thøgersen HC, Wiman B, Donaldson VH, Eddy RL, Marrinan J, Radziejewska E, Huber R, Shows TB, Magnusson S. (1986) Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry, 25, 4292-4301.
14. Beinrohr L, Harmat V, Dobó J, Lörincz Z, Gál P, Závodsky P. (2007) C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem, 282, 21100-21109.
15. Rauth G, Schumacher G, Buckel P, Müller-Esterl W. (1988) Molecular cloning of the cDNA coding for human C1 inhibitor. Protein Seq Data Anal, 1, 251-257.
16. Research Collaboratory for Structural Bioinformatics Protein Data Bank. www.pdb.org/pdb/home/home.do. Accessed November 25, 2011.
17. Bos IG, Hack CE, Abrahams JP. (2002) Structural and functional aspects of C1-inhibitor. Immunobiology, 205, 518-533.
18. Wagenaar-Bos IGA, Hack CE. (2006) Structure and function of C1-inhibitor. Immunol Allergy Clin North Am, 26, 615-632.
19. Späth PJ. (1992) In: Human protein data, (Haeberli A, ed.). VCH Verlagsges. mbH, Weinheim.
20. Levy LR, Lepow IH. (1959) Assay and properties of serum inhibitor of C01-esterase. Proc Soc Exp Biol Med, 101, 608-611.
21. Pensky J, Levy LR, Lepow IH. (1961) Partial purification of a serum inhibitor of C1-esterase. J Biol Chem, 236, 1674-1679.
22. Tosi M. (1998) Molecular genetics of C1 inhibitor. Immunobiology, 199, 358-365.
23. C1 inhibitor gene mutation database. http://hae.enzim.hu/. Accessed November 25, 2011.
24. Gadek JE, Hosea SW, Gelfand JA, Santaella M, Wickerhauser M, Triantaphyllopoulos DC, Frank MM. (1980) Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med, 302, 542-546.
25. Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CCM, Schreuder WO, Felt-Bersma RJF, Abbink JJ, Thijs LG, Hack CE. (1989) Proteolytic inactivation of plasma C1-inhibitor in sepsis. J Clin Invest, 84, 443-450.
26. Brackertz D, Isler E, Kueppers F. (1975) Half-life of C1INH in hereditary angioneurotic oedema (HAE). Clin Allergy, 5, 89-94.
27. Quastel M, Harrison R, Cicardi M, Alper CA, Rosen FS. (1983) Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest, 71, 1041-1046.
28. Woo P, Lachmann PJJ, Harrison RA, Amos N, Cooper C, Rosen FS. (1985) Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. Clin Exp Immunol, 61, 1-8.
29. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, von Hentig N, Klingebiel T, Kreuz W. (2010) Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion, 50, 354-360.
30. Bernstein JA, Ritchie B, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz DS, Obtulowicz K, Reshef A, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Schindel F, Craig TJ. (2010) Population pharmacokinetics of plasmaderived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol, 105, 149-154.
31. Chan JY, Burrowes CE, Habal FM, Movat HZ. (1977) The inhibition of activated factor XII (Hageman factor) by antithrombin III: the effect of other plasma proteinase inhibitors. Biochim Biophys Res Commun, 74, 150-158.
32. Pixley RA, Schapira M, Colman RW. (1985) The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem, 260, 1723-1729.
33. De Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. (1984) Inactivation of factor XII active fragment in normal plasma predominant role of C1-inhibitor. J Clin Invest, 73, 1542-1549.
34. Gigli I, Mason JW, Colman RW, Austen KF. (1970) Interaction of plasma kallikrein with the C1 inhibitor. J Immunol, 104, 574-581.
35. Schapira M, Scott CF, Colman RW. (1982) Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest, 69, 462-468.
36. Van der Graaf F, Koedam JA, Griffin JH, Bouma BN. (1983) Interaction of human plasma kallikrein and its light chain with C1 inhibitor. Biochemistry, 22, 4860-4866.
37. Wuillemin WA, Minnema M, Meijers JCM, Roem D, Eerenberg AJM, Nuijens JH, ten Cate H, Hack CE. (1995) Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood, 85, 1517-1526.
38. Harpel PC, Cooper NR. (1975) Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanism of interaction with C1s, plasmin, and trypsin. J Clin Invest, 55, 593-604.
39. Sim RB, Arlaud GJ, Colomb MG. (1980) Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. Biochim Biophys Acta, 612, 433-439.
40. Faulmann EL, Boyle MD. (1987) Regulation of the activation of C1 in serum. Mol Immunol, 24, 655-660.
41. Cooper NR. (1985) The classical complement pathway: activation and regulation of the first complement component. Adv Immunol, 37, 151-216.
42. Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T. (2000) Proteolytic activities of two types of mannose-binding lectinassociated serine protease. J Immunol, 165, 2637-2642.
43. Kaplan AP, Ghebrehiwet B. (2010) The plasma bradykininforming pathways and its interrelationships with complement. Mol Immunol, 47, 2161-2169.
44. Kaplan AP. (2010) Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol, 126, 918-925.
45. Cicardi M, Zingale LC, Zanichelli A, Deliliers DL, Caccia S. (2007) The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother, 8, 3173-3181.
46. Prematta MJ, Prematta T, Craig TJ. (2008) Treatment of hereditary angioedema with plasma-derived C1 inhibitor. Ther Clin Risk Manag, 4, 975-982.
47. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Günther A, Engelmann B, Preissner KT. (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA, 104, 6388-6393.
48. Müller F, Mutch NJ, SchenkWA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renné T. (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell, 139, 1143-1156.
49. Davis AE III, Mejia P, Lu F. (2008) Biological activities of C1 inhibitor. Mol Immunol, 45, 4057-4063.
50. Jiang H, Wagner E, Zhang H, Frank MM. (2001) Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med, 194, 1609-1616.
51. Nielsen EW, Waage C, Fure H, Brekke OL, Sfyroera G, Lambris JD, Mollnes TE. (2007) Effect of supraphysiological levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol Immunol, 44, 1819-1826.
52. Ratnoff OD, Pensky J, Ogston D, Naff GB. (1969) The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C01r subcomponent of the first component of complement by serum C01 esterase inhibitor. J Exp Med, 129, 315-331.
53. Brown EW, Ravindran S, Patston PA. (2002) The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism. Blood Coagul Fibrinolysis, 13, 711-714.
54. Ra°nby M, Bergsdorf N, Nilsson T. (1982) Enzymatic properties of one-and two-chain forms of tissue plasminogen activator. Thromb Res, 27, 175-183.
55. Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. (2008) C1 inhibitor: just a serine protease inhibitor?, New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther, 8, 1225-1240.
56. Davis AE. III, Lu F, Mejia P. (2010) C1 inhibitor, a multifunctional serine protease inhibitor. Thromb Haemost, 104, 886-893.
57. Rent R, Myhrman R, Fiedel BA, Gewurz H. (1976) Potentiation of C1-esterase inhibitor activity by heparin. Clin Exp Immunol, 23, 264-271.
58. Wuillemin WA, te Velthuis H, Lubbers YTP, de Ruig CP, Eldering E, Hack CE. (1997) Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulphate species are effective inhibitors of in vitro complement activation in plasma. J Immunol, 159, 1953-1960.
59. Bos IGAC, van Mierlo GJ, Bleeker WK, Rigter GMM, te Velthuis H, Dickneite G, Hack CE. (2001) The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model. Int Immunopharmacol, 1, 1583-1595.
60. Pixley RA, Schmaier A, Colman RW. (1987) Effect of negatively charged activating compounds on inactivation of factor XIIa by C1 inhibitor. Arch Biochim Biophys, 256, 490-498.
61. Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, Hack CE. (1996) Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem, 271, 12913-12918.
62. Rossi V, Bally I, Ancelet S, Xu Y, Frémeaux-Bacchi V, Vives RR, Sadir R, Thielens N, Arlaud GJ. (2010) Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding. J Immunol, 184, 4982-4989.
63. Lomas DA, Belorgey D, Mallya M, Miranda E, Kinghorn KJ, Sharp LK, Phillips RL, Page R, Robertson AS, Crowther DC. (2005) Molecular mousetraps and the serpinopathies. Biochem Soc Trans, 33, 321-330.
64. Storm D, Herz J, Trinder P, Loos M. (1997) C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J Biol Chem, 272, 31043-31050.
65. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. (1990) Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA, 87, 3753-3757.
66. Vogelaar EF, Brummelhuis HGJ, Krijnen HW. (1974) Contributions to the optimal use of human blood. III. Large-scale preparation of human C1 esterase inhibitor concentrate for clinical use. Vox Sang, 26, 118-127.
67. Pelzer H, Heber H, Heimburger N, Preis HM, Naumann H., inventors; Behringwerke Aktiengesellschaft, assignee. Verfahren zur Herstellung des C1-Inaktivators und seine Verwendung. European patent 0, 101, 935 B1. May 7, 1986.
68. Fuhge P, Gratz P, Geiger H. (1990) Modern methods for the manufacture of coagulation factor concentrates. Transfus Sci, 11, 23S-33S.
69. Alsenz J, Loos M. (1987) Simplified methods for the purification, quantitation, and functional estimation of human complement C1-inhibitor (C1-INH) with a monoclonal anti-C1-INH antibody. J Immunol Methods, 96, 107-114.
70. Prograis LJ, Hammer CH, Katusha K, Frank MM. (1987) Purification of C1 inhibitor: a new approach for the isolation of this biologically important plasma protease inhibitor. J Immunol Methods, 99, 113-122.
71. Wickerhauser M, Williams C, Kolen BL, Busby TF. (1987) Heat stability of lyophilized C1 inactivator concentrates. Vox Sang, 53, 1-6.
72. Benny AG, Brimer CM. (1988) Chromatographic procedure for preparation of a high-purity C1 esterase inhibitor concentrate. J Chromatogr, 433, 363-366.
73. Teh LC, Froger M. (1992) Evaluation of the chromatographic procedure for the preparation of a high-purity C1-esterase inhibitor concentrate from cryosupernatant plasma. J Chromatogr, 582, 65-70.
74. Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, Zerlauth G, Schwarz HP. (1998) A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion, 83, 540-549.
75. Hetzl E, (2011) Personal communication. (Baxter AG, Vienna). February 1.
76. Pilatte Y, Hammer CH, Frank MM, Fries LF. (1989) A new simplified procedure for C1 inhibitor purification. A novel use for jacalin-agarose. J Immunol Methods, 120, 37-43.
77. Donaldson VH, Falconieri MW. (1993) A modification of an affinity procedure for purification of human C1 inhibitor that provides a homogeneous stable preparation. J Immunol Methods, 157, 101-104.
78. Dubin A, Potempa J, Travis J. (1990) Isolation of nine human plasma proteinase inhibitors by sequential affinity chromatography. Prep Biochem, 20, 63-74.
79. Poulle M, Burnouf-Radosevich M, Burnouf T. (1994) Largescale preparation of highly purified human C1-inhibitor for therapeutic use. Blood Coagul Fibrinolysis, 5, 543-549.
80. Schoenhofer W, Schwarz HP, Zoechling O, Linnau Y., inventors; Baxter Healthcare Corporation, assignee. Method for production of a C1 esterase inhibitor (C1INH)-containing composition. US patent application 2001/0019839 A1. September 6, 2001.
81. Koenderman AHL, Hiemstra H, Over J, EijkhoutHW, Tissing MH, Hack CE, Kleine A, Hermens WT, Strengers PWF. (1999) Cetor1, a new C1-inhibitor concentrate and its use for treating HAE type I and AMI (Abstract). Plasma Product Biotechnology Meeting 1999, Daydream Island, Australia, 1999.
82. Terpstra FG, Kleijn M, Koenderman AHL, Over J, van Engelenburg FAC, Schuitemaker H, van't Wout AB. (2007) Viral safety of C1-inhibitor-NF. Biologicals, 35, 173-181.
83. Williams C, Wickerhauser M, Busby TF, Ingham KC. (1984) Pasteurization of C1 inactivator in the presence of citrate salts. Vox Sang, 46, 260-269.
84. Cicardi M, Mannucci PM, Castelli R, Rumi MG, Agostoni A. (1995) Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion, 35, 209-212.
85. Waytes AT, Rosen FS, Frank MM. (1996) Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med, 334, 1630-1634.
86. Brummelhuis HGJ, Over J, Duivis-Vorst CC, Wilson-de Stürler LA, Ates G, Hoek PJ, Reerink-Brongers EE. (1983) Contributions to the optimal use of human blood. IX Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives. Vox Sang, 45, 205-216.
87. Keizer RJ, Kleine Budde I, Strengers PFW, Levi M, Beijnen JH, Huitema ADR. (2012) Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product C1 esterase inhibitor. J Clin Pharmacol, 52, 204-213.
88. De Serres J, Gröner A, Lindner J. (2003) Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert1 P) in hereditary angioedema: a review. Transfus Apher Sci, 29, 247-254.
89. CSL Behring. (2009) Berinert1 product monograph.
90. Wagenaar-Bos IGA, Drouet C, Aygören-Pursun E. et al. (2008) Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods, 338, 14-20.
91. Thelwell C, Rigsby P, Longstaff C. (2010) An international collaborative study to establish the 1st WHO International Standards for C1-inhibitor, plasma and concentrate, WHO/BS/10.2144. Expert Committee on Biological Standardization, Geneva, October 2010. http://whqlibdoc.who. int/hq/2010/WHO_BS_10.2144_eng.pdf. Accessed November 25, 2011.
92. De Smet BJGL, de Boer JP, Agterberg J, Rigter G, Bleeker WK, Hack CE. (1993) Clearance of human native, proteinasecomplexed, and proteolytically inactivated C1-inhibitor in rats. Blood, 81, 56-61.
93. Nuijens JH, HuijbregtsCCM, vanMierloGM, HackCE. (1987) Inactivation of C1-inhibitor by proteases: demonstration by a monoclonal antibody of a neo-determinant on inactivated, non-complexed C1-inhibitor. Immunology, 61, 387-389.
94. Nzeako UC, Frigas E, Tremaine WJ. (2001) Hereditary angioedema: a broad review for clinicians. Arch Int Med, 161, 2417-2429.
95. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, Fay AC, Longhurst HJ, Morrison L, Price A, Price M, Watters D. (2005) C1 inhibitor deficiency: consensus document. Clin Exp Immunol, 139, 379-394.
96. Pappalardo E, Cicardi M, Duponchel C, Carugati A, Choquet S, Agostoni A, Tosi M. (2000) Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol, 106, 1147-1154.
97. Cichon S, Martin L, Hennies HC, Müller F, van Driessche K, Karpushova A, Stevens W, Colombo R, Renné T, Drouet C, Bork K, Nöthen MM. (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet, 79, 1098-1104.
98. Binkley KE. (2010) Factor XII mutations, estrogen-dependent inherited angioedema, and related conditions. Allergy Asthma Clin Immunol, 6, 16.
99. Pappalardo E, Zingale LC, Cicardi M. (2004) C1 inhibitor gene expression in patients with hereditary angioedema: quantitative evaluation by means of real-time RT-PCR. J Allergy Clin immunol, 114, 638-644.
100. Frank MM, Gelfand JA, Atkinson JP. (1976) Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med, 84, 580-593.
101. Zuraw BL. (2008) Hereditary angioedema. N Engl J Med, 359, 1027-1036.
102. Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B. (2005) C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol, 27, 286-298.
103. Frank MM. (2008) 8. Hereditary angioedema. J Allergy Clin Immunol, 121 (2 Suppl.), S398-S401.
104. Agostoni A, Cicardi M. (1992) Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine, 71, 206-215.
105. Levi M, Hack CE, van Oers MH. (2006) Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med, 119, 3-5.
106. Bowen T, Cicardi M, Farkas H, et al. (2010) 2010 International consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. Allergy Asthma Clin Immunol, 6, 24.
107. Drouet C, Désormeaux A, Robillard J, Ponard D, Bouillet L., Martin L, Kanny G, Moneret-Vautrin DA, Bosson JL, Quesada JL, López-Trascasa M, Adam A. (2008) Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase p. J Allergy Clin Immunol, 121, 429-433.
108. Pickering RJ, Good RA, Kelly JR, Gewurz H. (1969) Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet, 1, 326-330.
109. Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. (2007) Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol, 98, 383-388.
110. Agostoni A, Bergamaschini L, Martignoni G, Cicardi M, Marasini B. (1980) Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy, 44, 299-301.
111. Joseph K, Tholanikunnel TE, Kaplan AP. (2010) Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Ann Allergy Asthma Immunol, 104, 50-54.
112. Bork K, Witzke G. (1989) Long-term prophylaxis with C1-inhibitor (C1INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol, 83, 677-682.
113. Levi M, Choi, G Picavet C, Hack CE. (2006) Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol, 117, 904-908.
114. Zuraw BL, Busse PJ, White M, et al. (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med, 363, 513-522.
115. Leimgruber A, Jaques WA, Spaeth PJ. (1993) Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy. Int Arch Allergy Immunol, 101, 107-112.
116. Alvarez JM. (2000) Successful use of C1 esterase inhibitor protein in a patient with hereditary angioneurotic edema requiring coronary artery bypass surgery. J Thorac Cardiovasc Surg, 119, 168-171.
117. Maeda S, Miyawaki T, Nomura S, Yagi T, Shimada M. (2003) Management of oral surgery in patients with hereditary or acquired angioedemas: review and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol, 96, 540-543.
118. Socker M, Boyle C, Burke M. (2005) Angio-oedema in dentistry: management of two cases using C1 esterase inhibitor. Dent Update, 32, 350-354.
119. Kirschfink M, Nürnberger W. (1999) C1 inhibitor in antiinflammatory therapy: from animal experiment to clinical application. Mol Immunol, 36, 225-232.
120. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. (2000) C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev, 52, 91-112.
121. Cai S, Dole VS, Bergmeier W, Scafidi J, Feng H, Wagner DD, Davis AE III. (2005) A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol, 174, 6462-6466.
122. Davis AE. III, Cai S, Liu D. (2007) C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology, 212, 313-323.
123. Thorgersen EB, Ludviksen JK, Lambris JD, Sfyroera G, Nielsen EW, Mollnes TE. (2010) Anti-inflammatory effects of C1-inhibitor in porcine and human whole blood are independent of its protease inhibition activity. Innate Immun, 16, 254-264.
124. Liu D, Gu X, Scafidi J, Davis AE III. (2004) N-Linked glycosylation is required for C1 inhibitor-mediated protection from endotoxin shock in mice. Infect Immun, 72, 1946-1955.
125. Zhang H, Li J, Barrington RA, Liang G, Qin G, Liu DX. (2007) An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitor. Biochim Biophys Res Commun, 359, 285-291.
126. Jansen PM, Eisele B, de Jong IW, Chang A, Delvos U, Taylor FB, Jr., Hack CE. (1998) Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol, 160, 475-484.
127. Liu D, Lu F, Qin G, Fernandes SM, Li J, Davis AE III. (2007) C1 inhibitor-mediated protection from sepsis. J Immunol, 179, 3966-3972.
128. Zwijnenburg PJG, van der Poll T, Florquin S, Polfliet MMJ, van den Berg TK, Dijkstra CD, Roord JJ, Hack CE, van Furth AM. (2007) C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice. J Infect Dis, 196, 115-123.
129. Hack CE, Voerman HJ, Eisele B, Keinecke HO, Nuijens JH, Eerenberg AJM, Ogilvie A, Strack van Schijndel RJM, Delvos U, Thijs LG. (1992) C1-esterase inhibitor substitution in sepsis. Lancet, 339, 378.
130. Hack CE, Ogilvie AC, Eisele B, Jansen PM, Wagstaff J, Thijs LG. (1994) Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res, 388, 335-357.
131. Marx G, Nashan B, Cobas Meyer M, Vangerow B, Schlitt HJ, Ziesing S, Leuwer M, Piepenbrock S, Rueckoldt H. (1999) Septic shock after liver transplantation for Caroli's disease: clinical improvement after treatment with C1-esterase inhibitor. Intensive Care Med, 25, 1017-1020.
132. Fronhoffs S, Luyken J, Steuer K, Hansis M, Vetter H, Walger P. (2000) The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients. Intensive Care Med, 26, 1566-1570.
133. Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen HU, Zürcher-Zenklusen R, Rieben R, Devay J, Hack CE, Lämmle B, WuilleminWA. (2002) C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med, 30, 1722-1728.
134. Guerrero R, Velasco F, Rodriguez M, Lopez A, Rojas R, Alvarez MA, Villalba R, Rubio V, Torres A, del Castillo D. (1993) Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J Clin Invest, 91, 2754-2760.
135. Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis AE III. (2003) C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol, 171, 2594-2601.
136. Dorresteijn MJ, Visser T, Cox LAE, Bouw MP, Pillay J, Koenderman AHL, Strengers PFW, Leenen LPH, van der Hoeven JG, Koenderman L, Pickkers P. (2010) C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia. Crit Care Med, 38, 2139-2145.
137. Ogilvie AC, Baars JW, Eerenberg AJM, Hack CE, Pinedo HM, Thijs LG, Wagstaff J. (1994) A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of highdose interleukin 2. Br J Cancer, 69, 596-598.
138. Nürnberger W, Heying R, Burdach S, Göbel U. (1997) C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Haematol, 75, 95-101.
139. Strüber M, Hagl C, Hirt SW, Cremer J, HarringerW, Haverich A. (1999) C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med, 25, 1315-1318.
140. Heying R, Nürnberger W, Spiekerkötter U, Göbel U. (1998) Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate. Bone Marrow Transplant, 21, 947-949.
141. Tassani P, Kunkel R, Richter JA, Oechsler H, Lorenz HP, Braun SL, Eising GP, Haas F, Paek SU, Bauernschmitt R, Jochum M, Lange R. (2001) Effect of C1-esterase-inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates. J Cardiothorac Vasc Anesth, 15, 469-473.
142. Arzneimittelkommission der deutschen ärzteschaft. (2000) Schwerwiegende Thrombenbildung nach Berinert1 HS. Deutsches ärzteblatt, 97, A-1016.
143. Murohara T, Guo J-P, Delyani JA, Lefer AM. (1995) Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury. Methods Find Exp Clin Pharmacol, 17, 499-507.
144. Horstick G, Heimann A, Götze O, Hafner G, Berg O, Böehmer P, Becker P, Darius H, Rupprecht HJ, Loos M, Bhakdi S, Meyer J, Kempski O. (1997) Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation, 95, 701-708.
145. Buerke M, Murohara T, Lefer AM. (1995) Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation, 91, 393-402.
146. Bauernschmitt R, Böhrer H, Hagl S. (1998) Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med, 24, 635-638.
147. De Zwaan C, Kleine AH, Diris JHC, Glatz JFC, Wellens HJJ, Strengers PFW, Tissing M, Hack CE, van Dieijen-Visser MP, Hermens WT. (2002) Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J, 23, 1670-1677.
148. Thielmann M, Marggraf G, Neuhäuser M, Forkel J, Herold U, Kamler M, Massoudy P, Jakob H. (2006) Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg, 30, 285-293.
149. Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, Guccione F, Dioguardi P, Ruvolo G. (2007) Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg, 32, 326-332.
150. De Simoni MG, Rossi E, Storini C, Pizzimenti S, Echart C, Bergamaschini L. (2004) The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am J Pathol, 164, 1857-1863.
151. Storini C, Rossi E, Marrella V, Distaso M, Veerhuis R, Vergani C, Bergamaschini L, de Simoni MG. (2005) C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis, 19, 10-17.
152. Gesuete R, Storini C, Fantin A, Stravalaci M, Zanier ER, Orsini F, Vietsch H, Mannesse ML, Ziere B, Gobbi M, de Simoni MG. (2009) Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol, 66, 332-342.
153. Lehmann TG, Heger M, Munch S, Kirschfink M, Klar E. (2000) In vivo microscopy reveals that complement inhibition by C1 esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int, 13, Suppl. 1, S547-S550.
154. Bergamaschini L, Gorbo G, Gatti S, Caccamo L, Prato P, Maggioni M, Braidotti P, di Stefano R, Fassati LR. (2001) Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin Exp Immunol, 126, 412-420.
155. Nielsen EW, Mollnes TE, Harlan JM, Winn RK. (2002) C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic cross-clamping. Scand J Immunol, 56, 588-592.
156. NielsenEW, Mollnes TE, Harlan JM, Walsh MT, Wagner DD, Davis AE III. (2008) The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointestinal Liver Physiol, 295, G1042-G1049.
157. Salvatierra A, Velasco F, Rodriguez M, Alvarez A, Lopez-Pedrera R, Ramirez R, Carracedo J, Lopez-Rubio F, Lopez-Pujol J, Guerrero R. (1997) C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. Am J Respir Crit Care Med, 155, 1147-1154.
158. Fiane AE, Videm V, Johansen HT, Mellbye OJ, Nielsen EW, Mollnes TE. (1999) C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Immunopharmacology, 42, 231-243.
159. Hecker JM, Lorenz R, Appiah R, Vangerow B, Loss M, Kunz R, Schmidtko J, Mengel M, Klempnauer J, Piepenbrock S, Dickneite G, Neidhart H, Rückoldt H, Winkler M. (2002) C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplantation, 73, 688-694.
160. Przemeck M, Lorenz R, Vangerow B, Klempnauer J, Winkler M, Piepenbrock S. (2002) Pretreatment with C1-esterase inhibitor improves cardiovascular stability in small primates undergoing porcine kidney xenotransplantation. Transplant Proc. 34, 2383.
161. Poirier N, Blancho G. (2008) Recombinant human C1-inhibitor inhibits cytotoxicity induced by allo-and xenoantibodies. Transplant Proc, 40, 581-583.
162. Tillou X, Poirier N, Le Bas-Bernardet S, Hervouet J, Minault D, Renaudin K, Vistoli F, Karam G, Daha M, Soulillou JP, Blancho G. (2010) Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int, 78, 152-159.
163. Ruud TE, Aasen AO, Pillgram-Larsen J, Stadaas J, Aune S. (1986) Effects of protease inhibitor pretreatment on hemodynamic performances and survival rate in experimental, acute pancreatitis. Adv Exp Med Biol, 198, 413-421.
164. Yamaguchi H, Weidenbach H, Lührs H, Lerch MM, Dickneite G, Adler G. (1997) Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Gut, 40, 531-535.
165. Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, Bagnolo F, Agostoni A. (1995) Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc, 42, 301-305.
166. Schneider DT, Nürnberger W, Stannigel H, Bönig H, Göbel U. (1999) Adjuvant treatment of severe acute pancreatitis with C1 esterase inhibitor concentrate after haematopoietic stem cell transplantation. Gut, 45, 733-736.
167. Czaller I, Molnár K, Csuka D, Varga L, Farkas H. (2011) Successful outcome using C1-inhibitor concentrate in acute pancreatitis caused by hereditary angioedema. Gastroenterol Nurs, 34, 60-63.
168. Niederau C, Brinsa R, Niederau M, Lüthen R, Strohmeyer G, Ferrell LD. (1995) Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int J Pancreatol, 17, 189-196.
169. Henze U, Lennartz A, Hafemann B, Goldmann C, Kirkpatrick CJ, Klosterhalfen B. (1997) The influence of the C1-inhibitor BERINERT and the protein-free haemodialysate ACTIHAEMYL20% on the evolution of the depth of scald burns in a porcine model. Burns, 23, 473-477.
170. Khorram-Sefat R, Goldmann C, Radke A, Lennartz A, Mottaghy K, Afify M, Küpper W, Klosterhalfen B. (1998) The therapeutic effect of C1-inhibitor on gut-derived bacterial translocation after thermal injury. Shock, 9, 101-108.
171. Radke A, Mottaghy K, Goldmann C, Khorram-Sefat R, Kovacs B, Janssen A, Klosterhalfen B, Hafemann B, Pallua N, Kirschfink M. (2000) C1 inhibitor prevents capillary leakage after thermal trauma. Crit Care Med, 28, 3224-3232.
172. Kochilas L, Campbell B, Scalia R, Lefer AM. (1997) Beneficial effects of C1 esterase inhibitor in murine traumatic shock. Shock, 8, 165-169.
173. Pannell R, Kung W, Gurewich V. (2007) C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Haemost, 5, 1047-1054.
174. Gurewich V, Pannell R. (2009) Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis. Thromb Haemost, 102, 279-286.
175. Singer M, Jones AM. (2011) Bench-to-bedside review: the role of C1-esterase inhibitor in sepsis and other critical illnesses. Crit Care, 15, 203.
176. Longhurst HJ, Carr S, Khair K. (2006) C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol, 147, 11-17.
177. Bork K, Hardt J. (2011) Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol, 154, 81-88.
178. Eldering E, Nuijens JH, Hack CE. (1988) Expression of functional human C1 inhibitor in COS cells. J Biol Chem, 263, 11776-11779.
179. Cai S, Davis AE III. (2003) Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelialleukocyte adhesion. J Immunol, 171, 4786-4791.
180. Bos IGA, de Bruin EC, KaruntuYA, ModdermanPW, Eldering E, Hack CE. (2003) Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor. Biochim Biophys Acta, 1648, 75-83.
181. Longhurst H. (2008) Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs, 9, 310-323.
182. Varga L, Farkas H. (2008) Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor. Expert Rev Clin Immunol, 4, 653-661.
183. Koles K, van Berkel PHC, Pieper FR, Nuijens JH, Mannesse MLM, Vliegenthart JFG, Kamerling JP. (2004) N-and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology, 14, 51-64.
184. Koles K, van Berkel PHC, Mannesse MLM, Zoetemelk R, Vliegenthart JFG, Kamerling JP. (2004) Influence of lactation parameters on the N-glycosylation of recombinant human C1 inhibitor isolated from the milk of transgenic rabbits. Glycobiology, 14, 979-986.
185. Van Doorn MBA, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE, Schoemaker RC, Cohen AF, Nuijens J. (2005) A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol, 116, 876-883.
186. Choi G, Soeters MR, Farkas H, Varga L., Obtulowicz K, Bilo B, Porebski G, Hack CE, Verdonk R, Nuijens J, Levi M. (2007) Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion, 47, 1028-1032.
187. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE. (2010) Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol, 126, 821-827.
188. Cicardi M, Banerji A, Bracho F, et al. (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med, 363, 532-541.
189. Longhurst HJ. (2010) Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc Health Risk Manag, 6, 795-802.
190. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE. (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med, 363, 523-531.
191. Dyax Corp, Kalbitor Full Prescribing Information. www. kalbitor.com/hcp/rems/pdf/KalbitorFullPrescribingInformation. pdf. Accessed November 25, 2011.
192. Caballero T, López-Serrano C. (2006) Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol, 117, 476-477.
193. Beinrohr L, Dobó J, Závodsky P, Gál P. (2008) C1, MBLMASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. Trends Mol Med, 14, 511-521.